SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)
NEW YORK, /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gbt.
The investigation concerns whether Global Blood and certain of its officers and/or directors have violated federal securities laws.
On September 13, 2018, the website Stat published an article by Adam Feuerstein entitled "Global Blood's FDA filing plan for a sickle cell drug is riskier than you think". The article addressed Global Blood's drug voxelotor, a potential sickle cell disease treatment, and described "important risks that investors might be glossing over" with respect to voxelotor's U.S. Food and Drug Administration ("FDA") approval prospects. Citing the results of a recent Phase 3 clinical trial, the article asserted that "Global Blood lacks data demonstrating voxelotor reduces the frequency of crises", traditionally a necessary criterion for FDA approval of a sickle cell disease treatment, and further stated that "[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients." Accordingly, the article asserted that the Phase 3 results have "left Global Blood in a bind and searching for a new path to approval." Following publication of the Stat article, Global Blood's stock price fell sharply during intraday trading on September 13, 2018.
If you are aware of any facts relating to this investigation, or purchased Global Blood shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gbt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-global-blood-therapeutics-inc-gbt-300712290.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Company Codes: NASDAQ-NMS:GBT